Stock Events

Enzo Biochem 

$1.15
0
+$0+0% Monday 16:10

Statistics

Day High
1.15
Day Low
1.15
52W High
2.68
52W Low
1.13
Volume
4,800
Avg. Volume
1,019
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15OctExpected
Q3 2022
Q4 2022
Q1 2023
Q3 2023
Q4 2023
Q1 2024
Next
-0.31
-0.28
-0.25
-0.22
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0IHV.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen is a major player in the provision of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, directly competing with Enzo's life sciences products and diagnostic services.
Thermo Fisher Scientific
TMO
Mkt Cap234.95B
Thermo Fisher Scientific offers a broad range of reagents, instruments, and consumables used in biomedical research and diagnostics, overlapping with Enzo Biochem's market offerings.
Illumina
ILMN
Mkt Cap20.93B
Illumina provides sequencing and array-based solutions for genetic and genomic analysis, competing in the genomics space where Enzo also operates.
Bio-Rad Laboratories
BIO
Mkt Cap9.35B
Bio-Rad Laboratories manufactures and supplies products and systems used for gene expression, protein purification, and analysis, which are areas Enzo Biochem is involved in.
Quest Diagnostics
DGX
Mkt Cap17.47B
Quest Diagnostics is a provider of diagnostic testing, information, and services that competes with Enzo Biochem's diagnostic services segment.
Labcorp
LH
Mkt Cap19.3B
Laboratory Corporation of America offers clinical laboratory tests and services, and end-to-end drug development services, competing with Enzo's diagnostic and research product offerings.
Agilent Technologies
A
Mkt Cap41.06B
Agilent Technologies provides instruments, services, consumables, applications, and expertise, focusing on life sciences, diagnostics, and applied chemical markets, competing with Enzo Biochem in several key areas.
PERKINELMER INC
PKI
Mkt Cap16.9B
PerkinElmer provides products, services, and solutions for the diagnostics, life sciences, and applied services markets, directly competing with Enzo Biochem in multiple segments.
Bruker
BRKR
Mkt Cap10.17B
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions that compete with Enzo Biochem's life science and diagnostic products.
Guardant Health
GH
Mkt Cap3.15B
Guardant Health focuses on liquid biopsies and cancer diagnostics, competing in the precision medicine and diagnostics space where Enzo Biochem is also aiming to grow.

About

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ?STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Show more...
CEO
Mr. Barry W. Weiner
Employees
451
Country
US
ISIN
US2941001024

Listings